{"name":"EyeBiotech Ltd.","slug":"eyebiotech-ltd","ticker":"","exchange":"","domain":"","description":"EyeBiotech Ltd. is a biotechnology company focused on developing innovative treatments for ocular diseases. The company has a pipeline of three drug candidates, with two in Phase 2 and one in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"EYE103","genericName":"EYE103","slug":"eye103","indication":"Other","status":"phase_2"},{"name":"Tiespectus","genericName":"Tiespectus","slug":"tiespectus","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"EYE103","genericName":"EYE103","slug":"eye103","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tiespectus","genericName":"Tiespectus","slug":"tiespectus","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9zTmNIZ21PRXlTMm56d0txNi1VSHgzV2lDaExnZHFPdmZtNGZsZ1JYcEJ3b3QyODNlOE5SdWx0U0dZelNUNnRraUJYSlhrYWlSSWZfbUhZbzAzRmhBbmJWX0JxR0MtcHFFZGFrQnYtRW1kUVpESlFvODBIUUktQQ?oc=5","date":"2025-04-09","type":"pipeline","source":"China Daily","summary":"Pharma MNCs eye biotech sector - China Daily","headline":"Pharma MNCs eye biotech sector","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQaVlVNE1uMWdXSzlWdTZEQkFHSHJuNGV4OVVoSGlkT0hha2l6MHN1VTRNcnVsUzFiTmZxZnZQSWRsczVJa2l5TF9kX2xpZmx3OUxFanpvcjVrZXNXTDBaUGIzaHZTcE5LZk5JN0pnYmpEWmc4VDdiQnJULTZZSzRNN1l6dHdrdHMtMjF6UmtRNlRBa1JJeWZyd0NTQzF0NkNKR0NnV0VEb3g3V2IxUF9Fdg?oc=5","date":"2024-07-17","type":"pipeline","source":"BioPharm International","summary":"Merck Completes EyeBio Acquisition, Strengthens Eye Disease Portfolio - BioPharm International","headline":"Merck Completes EyeBio Acquisition, Strengthens Eye Disease Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNMFhkczgyVkdIejBtOFhoc2I0cFBFUE1zWWpmc1hhWlBxME1CaXZNaWdQdG1jM2pnOW5lb0RWU09RTUROZGVtR05rT3VVeW56eDJudldCWTNlbFhYT1ZKN1BBRjNpLTJadDBGa2RxT1hOMk1MbkdHNmN4cmdreE1vekRjdHhrZG9DT29z?oc=5","date":"2024-07-12","type":"pipeline","source":"Contract Pharma","summary":"Merck Completes Acquisition of EyeBio - Contract Pharma","headline":"Merck Completes Acquisition of EyeBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPUG1xYUtGVHhHYVl4UWQ3Z3U4RzhRWGJsMndlc1pzdmRLekE1ZDAxaWJnNEhldkliLUxHUVV4blFvMHdOWlBISDJUenI4cmtnYjBPOHZiX0ZxenN0LXJReXQtYUhKdko5ZEM1SFFCRDZCdFJwYno4YnF4R1JvRjZxTi1ZWi1xNTdQazR0ck1waUZRWmlvWGZ3?oc=5","date":"2024-05-30","type":"pipeline","source":"European Biotechnology Magazine","summary":"MSD grabs Eyebiotech Ltd for US$1.3bn upfront - European Biotechnology Magazine","headline":"MSD grabs Eyebiotech Ltd for US$1.3bn upfront","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1hLXFPOGw5TTVEdUFoRjlGcjZqQXpyM3ZwcXMzYnBFamoyU25neUg1eTIxZmo3VWVHVDJtdnh0Qmx3eDVzem9LNlBPcm1ndUh6SjYtV0VKcVpRSDgxLVd5NFRB?oc=5","date":"2024-05-30","type":"pipeline","source":"Pharmaceutical Executive","summary":"Pharma Pulse 5/30/24: Strategies for Conducting Strong, Efficient Peer Reviews of Papers, Smart Bandages Are on the Way & more - Pharmaceutical Executive","headline":"Pharma Pulse 5/30/24: Strategies for Conducting Strong, Efficient Peer Reviews of Papers, Smart Bandages Are on the Way ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSWl1ODRzc2RBeVQ4NTllUTRybG0xbmIxaHJuUFpPeVBXRGtiYVduRWJzMHd1TTdCZ1hJamZ5b3JFdEkzR0FlY2xmcjhkQ0JHbW5nRGNhRGg0RHVNSVByVUJZd19ESG4xejd1OW5kUnBKSUlaRDdNSUZlb1BjM0NobnJ3cWJnbE5abi12bEh5ZHo5cjU1dnM2enRnaFZHWFVyRlg0T3JFeV9mZw?oc=5","date":"2024-05-29","type":"deal","source":"Eyes On Eyecare","summary":"Merck to acquire Eyebiotech in deal worth up to $3B - Eyes On Eyecare","headline":"Merck to acquire Eyebiotech in deal worth up to $3B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPcFNtV0xwRGJ5MTlqOU1faUpjY2hGRU5hSTV2UHJZdm9paUNnN2c0OC0wcW5ueW1yZFRJMFZtMTNDOWd6ZWdoc2F3SzJRTkl5M3Y1QkVESjRGZkNNTnRJRE4zaDJNdFM1bFhDemFreHdWWGlVTVZVeldqWVBsTjZLZlVZbHF0RzVaSGlvbE8yLTVVRnpWVnZiWEh1SGI?oc=5","date":"2024-05-29","type":"deal","source":"Reuters","summary":"Merck to buy eye-focused drug developer EyeBio for as much as $3 bln - Reuters","headline":"Merck to buy eye-focused drug developer EyeBio for as much as $3 bln","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQcVYza2x0Qy1JdUZ4U0hUYVNCOW1NWW43YWV6elpjUE8yZ0F0WnRBNlVaWFgzUVYtQXFOYUFmNmJMQUxHWWN3Mkp6SGRUQUpTdmhHbnhPancwQU9VZDROT2JINmhmNU1qMjlsZDJ3aWpDYl9iWW1qZTB6dmE3SHkzbHBPQjFlcXdfcEdzRkREb1paZw?oc=5","date":"2024-05-29","type":"pipeline","source":"BioWorld News","summary":"Merck paying $1.3B up front for 3-year-old Eyebio - BioWorld News","headline":"Merck paying $1.3B up front for 3-year-old Eyebio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPUVZwY2dUTlNaZDVHSXNlSkRSamxHYWpEMmJJaTRkLU95UDkteWh6M2JTbENQYkItNkllODNGWlJhTHc5MEZaYlN5THIzQlJ0anlFSlpjZDd1ZV9rdDRqUXJ6MmU5b3JKQVBZeWZNNUxya1VZaXRrN0ZWRVhMVXpfU2JraG1wazg?oc=5","date":"2024-05-29","type":"deal","source":"Business Wire","summary":"Merck to Acquire EyeBio - Business Wire","headline":"Merck to Acquire EyeBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOTjl6VVhHYXIyMG1IT19BZlhDWlpvOGVJNHg1N0tMYVVlVmhnZ2piS1pubkpSU0JwUklJZTJERXYteFBkWmRMOVBMQTRPLU1jSlJLanBKUVN0OVJOYXlnQ2tnUWRsaVh6TElXQThhUm13cGRKLWdKN0M2blZjVmhkYkt3?oc=5","date":"2024-05-29","type":"deal","source":"Contract Pharma","summary":"Merck Agrees to Acquire EyeBio - Contract Pharma","headline":"Merck Agrees to Acquire EyeBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9iVlhGQ0lwTVVKSFZKR1VydTRRQ3RuYmVaQWVTRnJUODVJWjhSR3NvMXlBbWcxUHhqV3U3ZXpqeV9Od0ljdDdiQ2w0MDVzYWwxbFFubjdSaTRBQmlvckE?oc=5","date":"2022-05-11","type":"pipeline","source":"Pharmaceutical Executive","summary":"Challenging Assumptions - Pharmaceutical Executive","headline":"Challenging Assumptions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNN2tvcGZDa0oyWk0yNy1qUjFSbl9PNUJLNlZOMEdVYXR1Y1FxakJDUmtkSUxULU1WeV9VemdZWDlZRFBvMzVMTDZINWczeGZIRWR5VDZxa2JmWkNzRjJ6anZMNTlGenFOY2RvdVRtZDNwUWh4QzRGZlpET2o2M1diWVZHRS1SSDN0ejlIejRqYURQTHdtekVtMUFhTUswcndBQzk5bW1XYzA4d1ZjOGc?oc=5","date":"2022-02-22","type":"pipeline","source":"Ophthalmology Times","summary":"EyeBiotech Ltd. raises $65 million to develop new eye disease therapies - Ophthalmology Times","headline":"EyeBiotech Ltd. raises $65 million to develop new eye disease therapies","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}